DUBLIN--(BUSINESS WIRE)--The "Anticoagulants Market by Drug Class, Route of Administration, and Application, Pulmonary Embolism, and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2025" report has been added to ResearchAndMarkets.com's offering.
The global anticoagulants market was valued at $24,265 million in 2017, and is expected to reach $43,427 million by 2025, growing at a CAGR of 7.5% from 2018 to 2025.
The global anticoagulants market is expected to grow at a significant rate during the forecast period, owing to increasing prevalence of venous thromboembolism (VTE) and cardiovascular disease across the world, growing adoption of novel oral anticoagulants (NOACs), and growing awareness of NOACs in developing regions.
Furthermore, increasing obese and geriatric population and growing demand of novel therapeutics are anticipated to further influence the market growth during the forecast period.
On the other side, higher price of NOACs and lack of antidots for NOACs impede the market growth.
Profiles for:
Key Players
- Aspen Holdings
- Bayer AG
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company Ltd.
-
GlaxoSmithKline PLC
- Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
- Pfizer Inc.
- Portola Pharmaceuticals Inc.
- Sanofi S.A.
Other Players
- Armetheon Inc.
- Astrazeneca
- Celgene Corporation
Key Topics Covered
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
Chapter 4: Anticoagulants Market, by Drug Class
Chapter 5: Anticoagulants Market, by Route of Administration
Chapter 6: Anticoagulants Market, by Application
Chapter 7: Anticoagulants Market by Region
Chapter 8: Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/jlbk3s/the_global_market?w=4
